ISSN: 0034-8376
eISSN: 2564-8896
< Back

Abstract

Standard Treatment with Bevacizumab as Targeted Therapy in Cervical Cancer

VOLUME - NUMBER / (Forthcoming Articles)

Isabel Enríquez-Aceves, Department of Medical Oncology, Hospital del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estados (ISSSTE), León, Guanajuato, México
Tatiana Galicia-Carmona, Clinical Research and Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico
Jaime A. Coronel-Martínez, Departments of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico
Raquel Espinosa-Romero, Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico
Germán Calderillo-Ruíz, Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico
Patricia Cortés-Esteban, Department of Medical Oncology, Centro Médico Nacional 20 de Noviembre, Mexico City, Mexico
Lucely Cetina-Pérez, Department of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient’s quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

Keywords: Bevacizumab. Cervical. Cancer. Metastatic antiangiogenic.

Full Article in PDF